--- title: "LEADS BIOLABS-B (9887.HK) fluctuates at a high level, with increasing divergence in sector capital" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/273487622.md" description: "On January 23rd, LEADS BIOLABS-B rebounded in the early session but fell back in the afternoon, with short-term funds showing a reduction in positions at high levels. The biotechnology sector has shown significant volatility this week, with industry news such as new drug progress and collaboration dynamics frequently becoming market hotspots. There were rumors that the company's new drug project was approved to enter the clinical stage, but overall sector funds did not see significant inflows, leading to divergent trading sentiment. The market generally believes that the positive dynamics of new drugs are at a stage, but due to factors such as tightening industry regulations, the motivation for funds to chase higher is limited. The stock price has frequently oscillated at high levels, with intraday trading volume gradually shrinking, indicating weak upward momentum. Although the technical trend maintains a bullish pattern, the decline in trading volume dilutes technical signals, and funding discrepancies persist. The focus is on whether short-term trading volume can effectively rebound; if there are no further catalysts in the news, the space for breaking new highs is limited. Conversely, if the industry sees new developments, it may bring temporary relief. In the context of high-level oscillation, it is necessary to closely monitor changes in main funds and the overall linkage of the sector. It is recommended that investors adopt a defensive approach, grasp the rhythm in conjunction with sector news, and strictly control position management" datetime: "2026-01-26T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273487622.md) - [en](https://longbridge.com/en/news/273487622.md) - [zh-HK](https://longbridge.com/zh-HK/news/273487622.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273487622.md) | [English](https://longbridge.com/en/news/273487622.md) # LEADS BIOLABS-B (9887.HK) fluctuates at a high level, with increasing divergence in sector capital On January 23rd, LEADS BIOLABS-B saw a brief rebound in the morning but fell back in the afternoon, with short-term funds showing a reduction in positions at high levels. The biotechnology sector experienced significant fluctuations this week, with industry news such as new drug developments and collaboration dynamics frequently becoming market hotspots. There were previous rumors that the company's new drug project had been approved to enter the clinical stage, but overall sector funds did not show significant inflows, leading to a divergence in trading sentiment. The market generally believes that the positive dynamics of new drugs are at a stage, but due to factors such as tightening industry regulations, the motivation for funds to chase higher prices is limited. Stock prices have frequently oscillated at high levels, and the intraday trading volume has gradually shrunk, indicating weak upward momentum. Although the technical trend maintains a bullish pattern, the decline in trading volume has diluted technical signals, and fund divergence continues. The focus is on whether short-term trading volume can effectively rebound; if there are no further catalysts from the news front, the space for breaking new highs is limited. Conversely, if there are new developments in the industry, it may bring temporary relief. In the context of high-level oscillations, it is essential to closely monitor changes in major funds and the overall linkage of the sector. Investors are advised to adopt a defensive approach, grasping the rhythm in conjunction with sector news and strictly controlling position management ### 相關股票 - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [LEADS BIOLABS-B (09887.HK)](https://longbridge.com/zh-HK/quote/09887.HK.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) ## 相關資訊與研究 - [Novo Nordisk, United Bio-Technology Report Positive Mid-stage Clinical Data for UBT251 in China](https://longbridge.com/zh-HK/news/280426128.md) - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md) - [BankThink Banks should avoid the self-inflicted wound of negative messaging](https://longbridge.com/zh-HK/news/281012124.md) - [These 3 Defensive Stocks Just Hit 52-Week Highs — Should You Lock In Gains?](https://longbridge.com/zh-HK/news/280512209.md) - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md)